Teclistamab improves outcomes in relapsed MM, phase III trial finds
https://cancerletter.com/clinical-roundup/20260605_9b/
An international phase III study showed that patients with relapsed multiple myeloma treated with teclistamab lived longer and remained in remission significantly longer than patients receiving standard therapies. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all […]
